HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy
Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, Kyung Mann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Paul M. Sondel*
Research output: Contribution to journal › Journal Article › peer-review
17Scopus
citations
Fingerprint
Dive into the research topics of 'HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy'. Together they form a unique fingerprint.